Beta-globin gene therapy - bluebird bio

Drug Profile

Beta-globin gene therapy - bluebird bio

Alternative Names: BB305-beta-A(T87Q)-globin-gene-therapy-bluebird-bio; Beta-globin-gene-therapy-bluebird-bio; HPV569-beta-A(T87Q)-globin-gene-therapy-bluebird-bio; HPV569-beta-globin-gene-therapy-bluebird-bio; LentiGlobin; LentiGlobin-HPV569; LentiGlobin™ BB305; Lentiviral beta AT87Q-Globin vector

Latest Information Update: 07 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Genetix Pharmaceuticals
  • Developer bluebird bio
  • Class Antianaemics; Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Sickle cell anaemia
  • New Molecular Entity No

Highest Development Phases

  • Phase III Beta-thalassaemia
  • Phase I/II Sickle cell anaemia

Most Recent Events

  • 07 Nov 2017 Beta-globin gene therapy - bluebird bio is still in phase I development for Sickle cell anaemia in USA (IV, Infusion)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Sickle-cell-anaemia in USA (IV, Infusion)
  • 31 Oct 2017 Beta-globin gene therapy - bluebird bio receives Regenerative Medicine Advanced Therapy designation for Sickle cell anaemia in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top